$CRIS
CURIS INC Stock $cris

$cris Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000110820523000049 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$2.197M	$2.297M
YoY Change	-8.19%	11.67%
Cost Of Revenue	$74.00K	$24.00K
YoY Change	76.19%	-70.73%
Gross Profit	$2.123M	$2.273M
YoY Change	-9.7%	15.09%
Gross Profit Margin	96.63%	98.96%
Selling, General & Admin	$4.249M	$4.760M
YoY Change	-16.51%	-16.09%
% of Gross Profit	200.14%	209.41%
Research & Development	$10.01M	$9.140M
YoY Change	-18.75%	-20.07%
% of Gross Profit	471.6%	402.11%
Depreciation & Amortization	$64.00K	$64.00K
YoY Change	45.45%	77.78%
% of Gross Profit	3.01%	2.82%
Operating Expenses	$10.01M	$9.140M
YoY Change	-18.75%	-20.07%
Operating Profit	-$12.14M	-$11.63M
YoY Change	-19.41%	-23.17%
Interest Expense	$815.0K	$652.0K
YoY Change	403.09%	715.0%
% of Operating Profit
Other Income/Expense, Net	$177.0K	$68.00K
YoY Change	-120.14%	-106.97%
Pretax Income	-$11.96M	-$11.56M
YoY Change	-24.96%	-28.25%
Income Tax
% Of Pretax Income
Net Earnings	-$11.96M	-$11.60M
YoY Change	-24.96%	-27.99%
Net Earnings / Revenue	-544.42%	-505.01%
Basic Earnings Per Share	-$0.12	-$0.12
Diluted Earnings Per Share	-$0.12	-$0.12
COMMON SHARES
Basic Shares Outstanding	96.62M shares	96.62M shares
Diluted Shares Outstanding	96.69M shares	96.61M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$63.49M	$71.76M
YoY Change	-40.78%	-40.52%
Cash & Equivalents	$19.82M	$31.70M
Short-Term Investments	$43.67M	$40.06M
Other Short-Term Assets	$1.978M	$3.937M
YoY Change	-47.96%	14.92%
Inventory
Prepaid Expenses
Receivables	$2.386M	$2.314M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$67.85M	$78.01M
YoY Change	-40.16%	-38.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$561.0K	$625.0K
YoY Change	-28.9%	30.48%
Goodwill	$8.982M	$8.982M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.539M	$2.216M
YoY Change	299.84%	205.23%
Total Long-Term Assets	$16.46M	$16.53M
YoY Change	6.6%	13.25%
TOTAL ASSETS
Total Short-Term Assets	$67.85M	$78.01M
Total Long-Term Assets	$16.46M	$16.53M
Total Assets	$84.31M	$94.54M
YoY Change	-34.56%	-32.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.686M	$2.642M
YoY Change	-51.26%	-38.29%
Accrued Expenses	$5.776M	$4.246M
YoY Change	3.61%	-7.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.682M	$8.069M
YoY Change	-20.32%	-16.74%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$48.40M	$49.89M
YoY Change	-11.41%	-9.42%
Total Long-Term Liabilities	$48.40M	$49.89M
YoY Change	-11.41%	-9.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.682M	$8.069M
Total Long-Term Liabilities	$48.40M	$49.89M
Total Liabilities	$58.08M	$57.95M
YoY Change	-13.03%	-10.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.200B	-$1.200B
YoY Change	9.09%	9.09%
Common Stock	$1.199B	$1.197B
YoY Change	0.99%	1.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$26.22M	$36.59M
YoY Change
Total Liabilities & Shareholders Equity	$84.31M	$94.54M
YoY Change	-34.56%	-32.82%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$11.96M	-$11.60M
YoY Change	-24.96%	-27.99%
Depreciation, Depletion And Amortization	$64.00K	$64.00K
YoY Change	45.45%	77.78%
Cash From Operating Activities	-$7.868M	-$12.20M
YoY Change	-35.15%	-27.38%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$3.154M	$26.24M
YoY Change	-110.99%	-954.26%
Cash From Investing Activities	-$3.154M	$26.24M
YoY Change	-111.13%	-951.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-852.0K	-$2.006M
YoY Change	12.25%	21.72%
NET CHANGE
Cash From Operating Activities	-7.868M	-$12.20M
Cash From Investing Activities	-3.154M	$26.24M
Cash From Financing Activities	-852.0K	-$2.006M
Net Change In Cash	-11.87M	$12.04M
YoY Change	-176.86%	-155.87%
FREE CASH FLOW
Cash From Operating Activities	-$7.868M	-$12.20M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$7.868M	-$12.20M
YoY Change	-33.2%	-27.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001108205
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-30347
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	CURIS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3505116
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	128 Spring Street
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Building C - Suite 500
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Lexington
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02421
CY2023Q1	dei	City Area Code CityAreaCode	617
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	503-6500
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.01 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	CRIS
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	96617898	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31696000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19658000	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	40063000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	65965000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2314000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2975000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3937000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3521000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	78010000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	92119000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	625000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	689000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	635000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	635000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4076000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4401000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2216000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2022000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	8982000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	8982000	usd
CY2023Q1	us-gaap	Assets Assets	94544000	usd
CY2022Q4	us-gaap	Assets Assets	108848000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2642000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3193000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4246000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5679000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1181000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1141000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8069000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10013000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2492000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2800000	usd
CY2023Q1	cris	Royalty Guarantees Commitments Amount Noncurrent RoyaltyGuaranteesCommitmentsAmountNoncurrent	47393000	usd
CY2022Q4	cris	Royalty Guarantees Commitments Amount Noncurrent RoyaltyGuaranteesCommitmentsAmountNoncurrent	49483000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	57954000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	62296000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	227812500	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96617898	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96617898	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	227812500	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96607586	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96607586	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	966000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	966000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1196171000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1194769000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1160556000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1148997000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	9000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-186000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	36590000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	46552000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	94544000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	108848000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2297000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2057000	usd
CY2023Q1	us-gaap	Royalty Expense RoyaltyExpense	24000	usd
CY2022Q1	us-gaap	Royalty Expense RoyaltyExpense	82000	usd
CY2023Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	9140000	usd
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11435000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4760000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5673000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	13924000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	17190000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11627000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15133000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	652000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	80000	usd
CY2023Q1	cris	Non Cash Imputed Interest Expense NonCashImputedInterestExpense	584000	usd
CY2022Q1	cris	Non Cash Imputed Interest Expense NonCashImputedInterestExpense	1056000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	68000	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-976000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11559000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16109000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96613544	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96613544	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91645369	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91645369	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11559000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16109000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	195000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-342000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11364000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16451000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	46552000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1395000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	7000	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	195000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11559000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	36590000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	90707000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1718000	usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-342000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16109000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	75974000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11559000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16109000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	64000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	36000	usd
CY2023Q1	cris	Non Cash Lease Expense NonCashLeaseExpense	324000	usd
CY2022Q1	cris	Non Cash Lease Expense NonCashLeaseExpense	239000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1395000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1718000	usd
CY2023Q1	cris	Non Cash Imputed Interest Expense Net Of Imputed Interest NonCashImputedInterestExpenseNetOfImputedInterest	-77000	usd
CY2022Q1	cris	Non Cash Imputed Interest Expense Net Of Imputed Interest NonCashImputedInterestExpenseNetOfImputedInterest	-18000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	145000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-380000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-661000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1164000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	610000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	158000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1984000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3890000	usd
CY2023Q1	cris	Increase Decrease Operating Lease Liability IncreaseDecreaseOperatingLeaseLiability	-268000	usd
CY2022Q1	cris	Increase Decrease Operating Lease Liability IncreaseDecreaseOperatingLeaseLiability	-177000	usd
CY2023Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-640000	usd
CY2022Q1	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-706000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12199000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16815000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	17682000	usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	24972000	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	43925000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	21900000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	26243000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3083000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	7000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	0	usd
CY2023Q1	cris	Payments Of Future Royalty Liability Net Of Imputed Interest PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest	2013000	usd
CY2022Q1	cris	Payments Of Future Royalty Liability Net Of Imputed Interest PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest	1648000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2006000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1648000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	12038000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-21546000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20293000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40740000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32331000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19194000	usd
CY2023Q1	cris	Accrued Issuance Costs AccruedIssuanceCosts	0	usd
CY2022Q1	cris	Accrued Issuance Costs AccruedIssuanceCosts	172000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	661000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	1074000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1098000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Curis, Inc. is a biotechnology company seeking to develop and commercialize innovative drug candidates to treat cancer. Throughout these Condensed Consolidated Financial Statements, Curis, Inc. and its wholly owned subsidiaries are collectively referred to as “the Company,” “Curis,” “we,” “us,” or “our.”</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts its research and development programs both internally and through strategic collaborations. The Company has prioritized its lead clinical stage drug candidate emavusertib, an orally available small molecule inhibitor of Interleukin-1 receptor associated kinase 4 (“IRAK4”).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a collaboration with Genentech Inc. (“Genentech”), a member of the Roche Group, under which Genentech and F. Hoffmann-La Roche Ltd (“Roche”) are commercializing Erivedge® (vismodegib), a first-in-class orally administered small molecule Hedgehog signaling pathway antagonist. Erivedge is approved for the treatment of advanced basal cell carcinoma (“BCC”).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an exclusive collaboration agreement with Aurigene Discovery Technologies Limited (“Aurigene”) for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company’s business, including, but not limited to: the Company’s ability to obtain adequate financing to fund its operations; the Company’s ability to advance and expand its research and development programs; the Company’s ability to execute on its overall business strategies; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; the Company’s ability to comply with regulatory requirements; the Company’s ability to obtain and maintain applicable regulatory approvals and commercialize any approved product candidates; the ability of the Company and its wholly owned subsidiary, Curis Royalty, LLC (“Curis Royalty”), to satisfy the terms of the royalty interest purchase agreement (the “Oberland Purchase Agreement”) with entities managed by Oberland Capital Management, LLC (the “Purchasers”), and Lind SA LLC (the “Agent”), as collateral agent for the Purchasers; and the Company’s ability to maintain its current listing on Nasdaq.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it may receive and make under its current and potential future collaborations. The results of the Company’s operations have varied and will likely continue to vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will require substantial funds to maintain research and development programs and support operations. The Company has incurred losses and negative cash flows from operations since its inception. As of March 31, 2023, the Company had an accumulated deficit of $1.2 billion, and for the three months ended March 31, 2023, the Company incurred a net loss of $11.6 million and used $12.2 million of cash in operations. The Company expects to continue to generate operating losses in the foreseeable future. The Company anticipates that its $71.8 million of existing cash, cash equivalents and investments at March 31, 2023 will be sufficient to fund operations for at least 12 months from the date of filing this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of its control and it may be unable to raise financing when needed, or on terms favorable to the Company. If necessary funds are not available, the Company will have to delay, reduce the scope of, or eliminate some of its development programs, potentially delaying the time to market for or preventing the marketing of any of its product candidates.</span></div>
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1200000000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-11600000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12200000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	71800000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates and AssumptionsThe preparation of the Company’s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of revenue, expenses and certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company’s collaboration agreements; the collectability of receivables; the carrying value of goodwill; and the value of certain investments and liabilities. Actual results may differ from such estimates. These interim results are not necessarily indicative of results to be expected for a full year or subsequent interim periods.
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	600000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	600000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	40054000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	40063000	usd
CY2023Q1	cris	Available For Sale Securities Weighted Average Maturity AvailableForSaleSecuritiesWeightedAverageMaturity	P0Y3M18D
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	66151000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	188000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	65965000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	27400000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1494000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3152000	usd
CY2023Q1	cris	Research And Development Costs Current ResearchAndDevelopmentCostsCurrent	1564000	usd
CY2022Q4	cris	Research And Development Costs Current ResearchAndDevelopmentCostsCurrent	762000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1110000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1727000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	78000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	38000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4246000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5679000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3700000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4100000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3900000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4400000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P6Y
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8800000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	400000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	300000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0995
CY2019Q1	cris	Royalty Purchase Agreement Interest Rate RoyaltyPurchaseAgreementInterestRate	0.062
CY2019Q1	cris	Royalty Purchase Agreement Transaction Fees And Closing Costs RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts	600000	usd
CY2022Q4	cris	Royalty Purchase Agreement Liability Carrying Value RoyaltyPurchaseAgreementLiabilityCarryingValue	49483000	usd
CY2023Q1	cris	Royalty Purchase Agreement Issuance Costs Capitalized Amortization RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization	15000	usd
CY2023Q1	cris	Royalty Purchase Agreement Accretion Expense RoyaltyPurchaseAgreementAccretionExpense	569000	usd
CY2023Q1	cris	Payments Of Future Royalty Liability PaymentsOfFutureRoyaltyLiability	2674000	usd
CY2023Q1	cris	Royalty Purchase Agreement Liability Carrying Value RoyaltyPurchaseAgreementLiabilityCarryingValue	47393000	usd
CY2023Q1	cris	Collaboration Agreement Numberof Programs Licensed CollaborationAgreementNumberofProgramsLicensed	4	program
CY2023Q1	cris	Share Based Compensation Plans ShareBasedCompensationPlans	2	plan
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13673256	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.24
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M3D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4964050	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.70
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	10312	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.67
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1125903	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.91
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17501091	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.48
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M4D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8404265	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.19
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y11M15D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	17501091	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	2.48
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y8M4D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.59
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.62
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.036
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.014
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.017
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.15
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.16
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.10
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.11
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	12400000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1395000000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1718000	usd

Files In Submission

Name	View Source	Status
cris-20230331_def.xml	Edgar Link	unprocessable
cris-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
0001108205-23-000049-index-headers.html	Edgar Link	pending
0001108205-23-000049-index.html	Edgar Link	pending
0001108205-23-000049.txt	Edgar Link	pending
0001108205-23-000049-xbrl.zip	Edgar Link	pending
a2023-q1_exh101xzungx2023e.htm	Edgar Link	pending
cris-20230331.htm	Edgar Link	pending
cris-20230331.xsd	Edgar Link	pending
cris-3312023x10qexx311.htm	Edgar Link	pending
cris-3312023x10qexx312.htm	Edgar Link	pending
cris-3312023x10qexx321.htm	Edgar Link	pending
cris-3312023x10qexx322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cris-20230331_cal.xml	Edgar Link	unprocessable
cris-20230331_pre.xml	Edgar Link	unprocessable
cris-20230331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRIS
CURIS INC Stock $cris

2023 Q2 Form 10-Q Financial Statement

#000110820523000049 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS CURIS INC Stock $cris

2023 Q2 Form 10-Q Financial Statement

#000110820523000049 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS
CURIS INC Stock $cris